Although IFNα therapy has been established in the routine treatment of patients with high-risk melanoma [27], the mechanisms of anti-tumor effect and the action of IFNα in adjuvant melanoma therapy still remains unclear. This evidence concerns the gene IFNA2 and neoplasm.